%0 Journal Article
%T To BE or not to BE: non-invasive screening for Barrett’s esophagus, dysplasia and adenocarcinoma
%A Shah, Alok K.
%A Joshi, Virendra
%A Hartel, Gunter
%A Barbour, Andrew P.
%A Hill, Michelle M.
%J Translational Gastroenterology and Hepatology
%D 2019
%B 2019
%9 
%! To BE or not to BE: non-invasive screening for Barrett’s esophagus, dysplasia and adenocarcinoma
%K 
%X The EsophaCap™ DNA methylation biomarker validation study by Wang, Kambhampati and colleagues (1) follows a spade of reports (summarized in Table 1) aiming to develop screening tests for Barrett’s esophagus (BE). BE is a non-malignant metaplastic condition with little or no clinical symptoms. Arguably, the main importance of diagnosing BE is the increased risk of the patient to progress to esophageal adenocarcinoma (EAC).
%U https://tgh.amegroups.org/article/view/5056
%V 4
%P 
%@ 2415-1289